Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Comment by Golddetectoron Oct 18, 2021 9:30am
123 Views
Post# 34017348

RE:Milestones QIXLEEF Reborn Plenitude REDUVO

RE:Milestones QIXLEEF Reborn Plenitude REDUVO Focus on facts. Ignore trash talk. These below milestones never changed since may presentation. Stories and rumours will keep showing up along the way. This Q milestones is approaching. Bashing activities will be maximum. QIXLEEF results and Reduvo approval this Q is what matters it is a material change for tetra. The plan is to take QIXLEEF to market based on phase 2 trial results, I think it will be sold to big pharma based on interim results. It is a 10 week trial for each patients so Few patients completed their trials already. The fact reborn and plenitude have site added at end of august tells how successful is the trials. Once these reports out showing superiority of QIXLEEF over opioid we are going to see evaluation here. This will be 3 to 5 at the minimum. Gl longs.
<< Previous
Bullboard Posts
Next >>